Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection

NCT06585020 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

190

Enrollment

OTHER

Sponsor class

Conditions

Mycobacterium; Xenopi
Lung Diseases

Interventions

DRUG: Arikayce
DRUG: standard treatment

Sponsor

Centre Hospitalier Universitaire, Amiens

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]